<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04436497</url>
  </required_header>
  <id_info>
    <org_study_id>2019P003518A</org_study_id>
    <nct_id>NCT04436497</nct_id>
  </id_info>
  <brief_title>HEALEY ALS Platform Trial - Regimen A Zilucoplan</brief_title>
  <official_title>HEALEY ALS Platform Trial - Regimen A Zilucoplan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merit E. Cudkowicz, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ra Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial
      evaluating the safety and efficacy of investigational products for the treatment of ALS.

      Regimen A will evaluate the safety and efficacy of a single study drug, zilucoplan, in
      participants with ALS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial
      evaluating the safety and efficacy of investigational products for the treatment of ALS. This
      trial is designed as a perpetual platform trial. This means that there is a single Master
      Protocol dictating the conduct of the trial. The HEALEY ALS Platform Trial Master Protocol is
      registered as NCT04297683.

      Once a participant enrolls into the Master Protocol and meets all eligibility criteria, the
      participant will be eligible to be randomized into any currently enrolling regimen. All
      participants will have an equal chance of being randomized to any currently enrolling
      regimen.

      If a participant is randomized to Regimen A - Zilucoplan, the participant will complete a
      screening visit to assess additional Regimen A eligibility criteria. Once Regimen A
      eligibility criteria are confirmed, participants will complete a baseline assessment and be
      randomized in a 3:1 ratio to either active zilucoplan or matching placebo.

      Regimen A will enroll by invitation, as participants may not choose to enroll in Regimen A.
      Participants must first enroll into the Master Protocol and be eligible to participate in the
      Master Protocol before being able to be randomly assigned to Regimen A.

      For a list of enrolling sites, please see the HEALEY ALS Platform Trial Master Protocol under
      NCT04297683.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Progression</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory Function</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in respiratory function over time as measured by Slow Vital Capacity (SVC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Strength</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Change in muscle strength over time as measured isometrically using hand-held dynamometry (HHD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Comparison of rate of occurrence between groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Zilucoplan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Zilucoplan Administration: Subcutaneous injection
Dosage: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration: Subcutaneous injection
Dosage: Daily subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zilucoplan</intervention_name>
    <description>Drug: Zilucoplan Administration: Subcutaneous injection
Dosage: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight</description>
    <arm_group_label>Zilucoplan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Drug: Matching Placebo
Administration: Subcutaneous injection
Dosage: Daily subcutaneous injection</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The following inclusion criterion is in addition to the inclusion criteria specified
             in the Master Protocol (NCT NCT04297683).

               1. Vaccination with a quadrivalent meningococcal vaccine and meningococcal serotype
                  B vaccine at least 14 days prior to the first dose of study drug at the Baseline
                  (Day 0) visit. Meningococcal vaccines (including boosters) should be administered
                  in accordance with the study's vaccination worksheet.

        Exclusion Criteria:

          -  The following exclusion criteria are in addition to the exclusion criteria specified
             in the Master Protocol (NCT NCT04297683).

               1. History of meningococcal disease.

               2. Prior treatment with a complement inhibitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Merit Cudkowicz</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HEALEY Center for ALS at Massachusetts General Hospital</last_name>
    <phone>833-425-8257 (HALT ALS)</phone>
    <email>healeyalsplatform@mgh.harvard.edu</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 1, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Merit E. Cudkowicz, MD</investigator_full_name>
    <investigator_title>Chief, Neurology Department</investigator_title>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>Placebo-Controlled</keyword>
  <keyword>Double-Blind</keyword>
  <keyword>Regimen-Specific Appendix</keyword>
  <keyword>Lou Gehrig's Disease</keyword>
  <keyword>Zilucoplan</keyword>
  <keyword>Ra Pharmaceuticals</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

